Photo Credit: Nortonrsx
The Following is a summary of “Monitoring of Prostate-Specific Antigen In Men With Benign Prostate Enlargement Receue 5-Alpha Reductase Inhibitors: The Non-Interventional, Cross-Sectional Study of Real-Worry Practice of Urologists in Spain and Brazil,” Published In Public The January 2025 ISSUE OF BMC UROLOGY by Palacios et al.
Inconsistent Prostate-Specific Antigen Monitoring in Patients on 5-Alpha Reductase Inhibitors May Impact Prostate Cancer Outcomes.
RESEARCHERS DRIVED A RETROSPTIVE STUDY ON REAL-WORLD UROLOGY PRACTICES FOR PATIES RECEIVING 5-ALPHA REDUCTAS INHIBITORS.
They conducted a non-interventional, cross-sectional Study Collecting Data from 100 Urologists in Spain and 100 in Brazil Using Self-Reporting Questionnaires and Patient Record Forms. Endpoints Included Prostate-Specific Antigen Monitoring Frequency/Methodology, Concerns About 5-Alpha Reductase Inhibitors’ Effects, Biopsy Triggers, and Concerns When Switching Formulations.
The Results Showed That Over Half of Urologists Monitored Prostate-Specific Antigen Every 6 Months (Spain 59%, Brazil 58%). Preferred Methods Were the “Doubling Rule” (Spain 66%, Brazil 41%) and “Increase from Nadir” (Spain 28%, Brazil 43%). FEW Monitored UNADJUSTED VALUES (SPAIN 3%, Brazil 11%) Or Did Not Monitor at All (Spain 1%, Brazil 3%). Most ranked the potential for 5-alpha reductase inhibitors to mask prostate cancer as their top (Spain 65%, Brazil 56%). The Most Selected Biopsy Trigger was a doubled adjusted prostate-specific antigen level> 4 ng/ml after 6 months (Spain 39%, Brazil 37%). MANY WERE MODERATELY/VEY CONCERED ABOUT PROSTATE-SPECIFIC ANTIGEN CHANGES WHEN SWITCHING Formulations.
Investigators Identified a Need for Standard Guidance and Continous Education to Improve Prostate-Specific Antigen Monitoring and Interpretation in Patients Treated with 5-Alpha Reductase Inhibitors.
Source: bmcurol.biomedcentral.com/articles/10.1186/s12894-025-01701-1
